The global viscosupplementation market is on a strong growth trajectory, with projections indicating an increase from USD 2,167.3 million in 2024 to USD 3,777.4 million by 2034. This represents a compound annual growth rate (CAGR) of 5.7%, driven by the escalating demand for effective, non-invasive treatments for osteoarthritis (OA) and other lifestyle-related conditions.
Viscosupplementation, a non-surgical therapy that uses hyaluronic acid-based formulations, is gaining momentum as a preferred treatment for osteoarthritis. This therapy is particularly effective in managing joint pain, especially in patients suffering from knee osteoarthritis, and is becoming increasingly recognized for its clinical benefits. The rising prevalence of OA and the growing preference for non-surgical interventions are major factors fueling the global demand for viscosupplements.
Key Drivers of Market Growth:
- Rising Prevalence of Osteoarthritis:
As the global population ages, the incidence of osteoarthritis continues to rise, driving the demand for viscosupplementation therapies. These treatments provide an appealing solution for individuals seeking to manage OA symptoms without the need for surgery.
- Growing Preference for Non-Invasive Treatments:
Viscosupplementation offers a non-invasive alternative to surgical procedures, making it an attractive option for patients who prioritize shorter recovery times and fewer risks associated with invasive surgeries.
- Proven Clinical Benefits:
Clinical studies have demonstrated the significant efficacy of viscosupplementation products in managing knee osteoarthritis, improving patient outcomes, and enhancing the quality of life. The proven benefits of these therapies are encouraging increased interest from both healthcare professionals and patients alike, further driving market growth.
As the viscosupplementation market continues to expand, research and development efforts are focusing on creating new formulations and innovative delivery methods. These advancements are set to provide patients with access to the latest and most effective treatment options, ensuring the ongoing success and growth of the market in the years to come.
With its strong clinical track record and increasing demand for non-surgical treatments, the viscosupplementation market is well-positioned for sustained growth in the coming decade.
Viscosupplementation Trends on the Rise: Uncover the Full Scope with Our In-Depth Report!
Regional Insights:
- Asia Pacific: Dominates the global viscosupplementation market due to its large aging population and preference for non-surgical treatments. The region’s market is driven by cultural norms and a high incidence of osteoarthritis.
- North America: Expected to experience significant growth driven by the rising prevalence of osteoarthritis, well-developed healthcare infrastructure, and increasing demand for non-surgical procedures.
- China: The market in China is forecasted to grow at the highest CAGR of 9.0%, reflecting a substantial increase in demand for viscosupplementation.
- Europe and Japan: Both regions are poised for steady growth, with notable CAGRs of 4.0% and 8.5%, respectively.
Key Market Segments:
- Product Type: Three Injection Viscosupplementation is projected to capture 48.4% of the market share from 2024 to 2034.
- End User: Ambulatory Surgical Centers are expected to hold a significant market share of 31.9% during the same period.
Noteworthy Developments:
- In April 2022, Juniper Biologics and Kolon Life Sciences entered an agreement to license TissueGene-C low dose (TG-C LD), a single intra-articular injection treatment for knee osteoarthritis.
- May 2021 saw the launch of JOYCLU 30 mg intra-articular injection by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation.
- Anika Therapeutics, Inc. introduced Hyalofast, a hyaluronic acid-based scaffold for cartilage regeneration, at an event hosted by the International Cartilage Regeneration and Joint Preservation Society (ICRS).
Competitive Landscape:
Major players in the viscosupplementation market, including Sanofi S.A., Zimmer Biomet Holdings Inc., and Bioventus LLC, are focusing on developing advanced cross-linked hyaluronic acid products and expanding into new regions to gain a competitive edge.
Prominent Viscosupplementation Manufacturers:
- Anika Therapeutics Inc.
- Fidia Farmaceutici S.p.A.
- Ferring B.V.
- Seikagaku Corporation
- Chugai Pharmaceutical Co., Ltd.
- OrthogenRx Inc.
- Mylan N.V.
Key Segments:
By Product:
- Single Injection
- Three Injection
- Five Injection
By Application:
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Others
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Orthopedic Clinics
- Retail Pharmacies
- Online Sales
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube